{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:36:34Z","timestamp":1789565794639,"version":"build-2803163510"},"reference-count":107,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.abd.2023.08.004","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T06:40:09Z","timestamp":1705473609000},"page":"167-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Infections in the era of immunobiologicals"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-3831","authenticated-orcid":false,"given":"Ricardo","family":"Romiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-3551","authenticated-orcid":false,"given":"Andr\u00e9 Lu\u00eds da Silva","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-4790","authenticated-orcid":false,"given":"Adriana Maria","family":"Porro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-2580","authenticated-orcid":false,"given":"Heitor de S\u00e1","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-7842","authenticated-orcid":false,"given":"Luciane Donida Bartoli","family":"Miot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-5067","authenticated-orcid":false,"given":"Sandra Maria Barbosa","family":"Dur\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5512-4700","authenticated-orcid":false,"given":"Silvio Alencar","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2023.08.004_bib0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2023.08.004_bib0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.det.2014.09.009","article-title":"Ten years on: the impact of biologics on the practice of Dermatology","volume":"33","author":"Leonardi","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.abd.2023.08.004_bib0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/09546634.2019.1589643","article-title":"Biologics for chronic inflammatory skin diseases: an update for the clinician","volume":"31","author":"Yao","year":"2020","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2023.08.004_bib0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.autrev.2006.12.002","article-title":"Biologic therapies in psoriasis: a new therapeutic approach","volume":"6","author":"Gisondi","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.abd.2023.08.004_bib0025","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria - Anvisa [Internet]. [accessed 2023 Jun 24]. Available from: www.portal.anvisa.gov.br."},{"key":"10.1016\/j.abd.2023.08.004_bib0030","series-title":"Consenso Brasileiro de Psor\u00edase 2020: Algoritmo de Tratamento da Sociedade Brasileira de Dermatologia","year":"2020"},{"key":"10.1016\/j.abd.2023.08.004_bib0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/1744666X.2020.1801420","article-title":"Dupilumab for the treatment of adolescents with atopic dermatitis","volume":"16","author":"Senner","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.abd.2023.08.004_bib0040","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2023.08.004_bib0045","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.abd.2023.08.004_bib0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2023.08.004_bib0055","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort","volume":"65","author":"Wakkee","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0060","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2022.08.059","article-title":"Patients with hidradenitis suppurativa have a higher rate of postoperative infections","volume":"88","author":"Jefferson","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000478076","article-title":"Immunosuppression\/Infections across indications","volume":"53","author":"Al-Khalili","year":"2017","journal-title":"Curr Probl Dermatology"},{"key":"10.1016\/j.abd.2023.08.004_bib0070","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2017.07.047","article-title":"Serious infections among a large cohort of subjects with systemically treated psoriasis","volume":"77","author":"Dobry","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0075","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.jaad.2017.10.054","article-title":"Comment on \u201cSerious infections among a large cohort of subjects with systemically treated psoriasis.\u201d","volume":"78","author":"Arnold","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.abd.2023.08.004_bib0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.abd.2023.08.004_bib0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0090","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1590\/abd1806-4841.20131905","article-title":"Off-label use of rituximab in dermatology: pemphigus treatment","volume":"88","author":"Bomm","year":"2013","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of Immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.abd.2023.08.004_bib0100","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.abd.2023.08.004_bib0105","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.abd.2023.08.004_bib0110","series-title":"Consenso Brasileiro de Psor\u00edase 2012: Guias de Avalia\u00e7\u00e3o e Tratamento","year":"2012"},{"key":"10.1016\/j.abd.2023.08.004_bib0115","series-title":"Comp\u00eandio de Psor\u00edase","first-page":"221","article-title":"Avalia\u00e7\u00e3o pr\u00e9-tratamento biol\u00f3gico","author":"Lima","year":"2010"},{"key":"10.1016\/j.abd.2023.08.004_bib0120","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-\u03b3 assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.abd.2023.08.004_bib0125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10096-005-1377-8","article-title":"Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice","volume":"24","author":"Meier","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.abd.2023.08.004_bib0130","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1001\/jama.293.22.2746","article-title":"Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing","volume":"293","author":"Pai","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.abd.2023.08.004_bib0135","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2015.11.043","article-title":"Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS","volume":"74","author":"Gallitano","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0140","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.semarthrit.2021.08.013","article-title":"Safety of biologic treatments in solid organ transplant recipients: a systematic review","volume":"51","author":"Meyer","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.abd.2023.08.004_bib0145","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1473-3099(10)70101-8","article-title":"HIV-associated psoriasis: pathogenesis, clinical features, and management","volume":"10","author":"Morar","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.abd.2023.08.004_bib0150","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/ijd.14436","article-title":"Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis","volume":"58","author":"Plachouri","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0155","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/09546634.2018.1535690","article-title":"Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study","volume":"30","author":"Montes-Torres","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2023.08.004_bib0160","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2340\/00015555-2698","article-title":"Biologic therapies in hiv-infected patients with psoriasis: an Italian experience","volume":"97","author":"Bardazzi","year":"2017","journal-title":"Acta Der Venereol"},{"key":"10.1016\/j.abd.2023.08.004_bib0165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000508781","article-title":"Use of Anti-IL-17 monoclonal antibodies in HIV patients with erythrodermic psoriasis","volume":"12","author":"Pangilinan","year":"2020","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0170","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15277","article-title":"Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities","volume":"35","author":"Rob","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2023.08.004_bib0175","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/09564624221129406","article-title":"The use of dupilumab in patients with HIV","volume":"33","author":"Edmonds","year":"2022","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.abd.2023.08.004_bib0180","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjd.12326","article-title":"Tumour necrosis factor-\u03b1 inhibitor use in patients with psoriasis with organ transplantation","volume":"169","author":"Mansouri","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0185","doi-asserted-by":"crossref","first-page":"e5108","DOI":"10.1097\/MD.0000000000005108","article-title":"Anti-TNF\u03b1 therapy for chronic inflammatory disease in kidney transplant recipients","volume":"95","author":"Garrouste","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.abd.2023.08.004_bib0190","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1111\/ajd.13568","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: a case report","volume":"62","author":"Richetta","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0195","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/ecco-jcc\/jjaa062","article-title":"Ustekinumab is a safe and effective biological agent for crohn\u2019s disease in a liver transplant patient","volume":"14","author":"Peverelle","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.abd.2023.08.004_bib0200","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1684\/ejd.2020.3776","article-title":"Use of anti-IL 17A for psoriasis is not necessarily contraindicated in organ transplantation patients","volume":"30","author":"Di Altobrando","year":"2020","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0205","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11926-016-0572-1","article-title":"Fungal infections and new biologic therapies","volume":"18","author":"Vallabhaneni","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.abd.2023.08.004_bib0215","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.abd.2023.08.004_bib0220","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1378\/chest.124.6.2395","article-title":"Pulmonary Cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy","volume":"124","author":"Hage","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.abd.2023.08.004_bib0225","unstructured":"FDA Postmarket Drug Safety Information for Patients and Providers [Internet]. [accessed 2022 Nov 9]. Available from: http:\/\/wayback.archive-it.org\/7993\/20170112032015\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124185.htm."},{"key":"10.1016\/j.abd.2023.08.004_bib0230","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.abd.2023.08.004_bib0235","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/art.39468","article-title":"Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors","volume":"68","author":"Salt","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-017-1496-5","article-title":"One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry","volume":"20","author":"Harrold","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.abd.2023.08.004_bib0245","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40744-021-00352-6","article-title":"Real-world safety and effectiveness of golimumab in rheumatic diseases: post-marketing surveillance in Korea","volume":"8","author":"Kim","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.abd.2023.08.004_bib0250","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0255","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.abd.2023.08.004_bib0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.12788\/cutis.0088","article-title":"Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis","volume":"106","author":"Lee","year":"2020","journal-title":"Cutis"},{"key":"10.1016\/j.abd.2023.08.004_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0270","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/jof7121058","article-title":"Invasive fungal infections and targeted therapies in hematological malignancies","volume":"7","author":"Little","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.abd.2023.08.004_bib0275","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.abd.2023.08.004_bib0280","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.abd.2023.08.004_bib0285","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jdv.12508","article-title":"The risk of deep fungal infections during biologic therapy for psoriasis","volume":"28","author":"Jourabchi","year":"2014","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.abd.2023.08.004_bib0290","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15257","article-title":"Evaluating the risk\u2010to\u2010benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: a retrospective study with 494 patients","volume":"35","author":"Faraji","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2023.08.004_bib0295","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1590\/0037-8682-0222-2017","article-title":"Pulmonary paracoccidioidomycosis: a case report of reactivation in a patient receiving biological therapy","volume":"51","author":"Covre","year":"2018","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.abd.2023.08.004_bib0300","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11046-011-9403-0","article-title":"Paracoccidioidomycosis Induced by immunosuppressive drugs in a patient with rheumatoid arthritis and bone sarcoma: case report and review of the literature","volume":"172","author":"Woyciechowsky","year":"2011","journal-title":"Mycopathologia"},{"key":"10.1016\/j.abd.2023.08.004_bib0305","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/1352458518763091","article-title":"Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis","volume":"24","author":"Almeida","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.abd.2023.08.004_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abd.2021.07.003","article-title":"Hay RJ. Sporotrichosis: hyperendemic by zoonotic transmission, with atypical presentations, hypersensitivity reactions and greater severity","volume":"97","author":"Schechtman","year":"2022","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0315","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/jof5010002","article-title":"Paracoccidioidomycosis in immunocompromised patients: a literature review","volume":"5","author":"de Almeida","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.abd.2023.08.004_bib0320","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1590\/S0482-50042011000200005","article-title":"Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results","volume":"51","author":"Titton","year":"2011","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0325","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4269\/ajtmh.19-0616","article-title":"Biologics in leprosy: a systematic review and case report","volume":"102","author":"Cogen","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.abd.2023.08.004_bib0330","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/jdv.16764","article-title":"The risk of leprosy in patients using immunobiologics and conventional immunosuppressants for the treatment of dermatological and rheumatological diseases: a cohort study","volume":"35","author":"Martins Gomes","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.08.004_bib0335","article-title":"Case report: a case series of immunobiological therapy (Anti-TNF-\u03b1) for patients with erythema nodosum leprosum","volume":"9","author":"Mendes","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.abd.2023.08.004_bib0340","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jaad.2012.04.036","article-title":"Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management","volume":"67","author":"Abramson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0350","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s12026-017-8950-y","article-title":"Is there an association between pemphigus and hepatitis viruses? a population-based large-scale study","volume":"65","author":"Kridin","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.abd.2023.08.004_bib0355","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15783","article-title":"Prevalence and management of chronic hepatitis B in pemphigus and pemphigoid patients: new evidence for the safety of rituximab","volume":"35","author":"Aryanian","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2023.08.004_bib0360","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0365","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaad.2019.12.001","article-title":"Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study","volume":"85","author":"Chiu","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0370","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/09546634.2019.1657225","article-title":"How do we treat psoriasis patients with hepatitis C infections in real-world situations? a retrospective analysis of 34 patients","volume":"32","author":"Chularojanamontri","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2023.08.004_bib0375","unstructured":"Lok ASF, Bounis PAL. Hepatitis B virus reactivation associated with immunosuppressive therapy [Internet]. ed. UpToDate. [accessed 2023 Mar 24]. Available from: http:\/\/www.uptodate.com."},{"key":"10.1016\/j.abd.2023.08.004_bib0380","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0385","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety pro\ufb01le of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2023.08.004_bib0390","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3748\/wjg.v27.i19.2312","article-title":"Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics","volume":"27","author":"Akiyama","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.abd.2023.08.004_bib0395","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of hepatitis B virus: a review of clinical guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.abd.2023.08.004_bib0400","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2023.08.004_bib0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cia2.12209","article-title":"Dupilumab in atopic dermatitis patients with chronic hepatitis B","volume":"5","author":"Matsutani","year":"2022","journal-title":"Journal of Cutaneous Immunology and Allergy"},{"key":"10.1016\/j.abd.2023.08.004_bib0410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/DER.0000000000000845","article-title":"Systemic therapy for atopic dermatitis in older adults and adults with comorbidities: a scoping review and international eczema council survey","volume":"33","author":"Drucker","year":"2022","journal-title":"Dermatitis"},{"key":"10.1016\/j.abd.2023.08.004_bib0415","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","article-title":"Psoriasis: which therapy for which patient: focus on special populations and chronic infections","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0420","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-013-2378-0","article-title":"Long-term safety of anti-TNF-\u03b1 in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0425","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000439587","article-title":"Are anti-TNF-\u03b1 agents safe for treating psoriasis in hepatitis C virus patients with advanced liver disease? case reports and review of the literature","volume":"232","author":"Di Nuzzo","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.abd.2023.08.004_bib0430","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0435","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4103\/0378-6323.140301","article-title":"Use of rituximab in pemphigus patients with chronic viral hepatitis: report of three cases","volume":"80","author":"Kanwar","year":"2014","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.abd.2023.08.004_bib0440","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaad.2019.03.017","article-title":"A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the medical board of the national psoriasis foundation","volume":"81","author":"Baumrin","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0445","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2017.03.011","article-title":"Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis","volume":"80","author":"Lopez","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.abd.2023.08.004_bib0450","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.7326\/M20-6928","article-title":"The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy","volume":"174","author":"Curtis","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.abd.2023.08.004_bib0455","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/S0482-50042013000100002","article-title":"Consenso 2012 da Sociedade Brasileira de Reumatologia sobre vacina\u00e7\u00e3o em pacientes com artrite reumatoide","volume":"53","author":"Brenol","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.abd.2023.08.004_bib0465","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11926-013-0330-6","article-title":"Vaccination and inflammatory arthritis: overview of current vaccines and recommended uses in rheumatology","volume":"15","author":"M\u00fcller-Ladner","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.abd.2023.08.004_bib0470","unstructured":"CfDCaP (CDC). Immunization Schedules Atlanta [Internet]. 2022. Available from: https:\/\/www.cdc.gov\/vaccines\/schedules\/."},{"key":"10.1016\/j.abd.2023.08.004_bib0475","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaad.2013.06.046","article-title":"From the medical board of the National Psoriasis Foundation: vaccination in adult patients on systemic therapy for psoriasis","volume":"69","author":"Wine-Lee","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0480","first-page":"5","article-title":"Shingrix for herpes zoster: a review","volume":"24","author":"Shah","year":"2019","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.abd.2023.08.004_bib0485","series-title":"T\u00e9cnicas de aplica\u00e7\u00e3o e leitura da prova tubercul\u00ednica","author":"Minist\u00e9rio da Sa\u00fade","year":"2014"},{"key":"10.1016\/j.abd.2023.08.004_bib0490","series-title":"Tuberculose: guia de vigil\u00e2ncia epidemiol\u00f3gica","author":"Comit\u00ea T\u00e9cnico Cient\u00edfico de Assessoramento \u00e0 Tuberculose","year":"2002"},{"key":"10.1016\/j.abd.2023.08.004_bib0495","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/vaccines10020137","article-title":"The course of Anti-HBc antibodies over time in immuno compromised hosts","volume":"10","author":"Holtkamp","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.abd.2023.08.004_bib0500","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/MEG.0000000000001849","article-title":"Evaluation of hepatitis B vaccine efficacy and factors affecting vaccine nonresponse in patients receiving anti-tumor necrosis factor agents","volume":"33","author":"Okay","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0505","doi-asserted-by":"crossref","DOI":"10.1038\/srep32076","article-title":"Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial","volume":"6","author":"Sadlier","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.abd.2023.08.004_bib0510","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ecco-jcc\/jjaa099","article-title":"Safety and optimal timing of BCG vaccination in infants born to mothers receiving anti-TNF therapy for inflammatory bowel disease","volume":"14","author":"Park","year":"2020","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1016\/j.abd.2023.08.004_bib0515","author":"Sociedade Brasileira de Dermatologia"},{"key":"10.1016\/j.abd.2023.08.004_bib0520","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-022-01742-y","article-title":"Prevention and treatment of monkeypox","volume":"82","author":"Rizk","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.abd.2023.08.004_bib0525","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2007.08.030","article-title":"From the medical board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis","volume":"58","author":"Lebwohl","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.08.004_bib0530","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-Guideline on the systemic treatment of psoriasis vulgaris \u2013 update apremilast and secukinumab \u2013 EDF in cooperation with EADV and IPC","volume":"31","author":"Nast","year":"2017","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"10.1016\/j.abd.2023.08.004_bib0535","first-page":"e1","article-title":"Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris \u2012 Update 2015 \u2012 EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eurn Acad Dermatol Venereol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623002441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059623002441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:50Z","timestamp":1747666850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059623002441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0365059623002441"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2023.08.004","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections in the era of immunobiologicals","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2023.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.","name":"copyright","label":"Copyright"}]}}